WallStreetZenWallStreetZen

NASDAQ: CGEM
Cullinan Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CGEM

Based on 5 analysts offering 12 month price targets for Cullinan Therapeutics Inc

Min Forecast
$27.00+120.77%
Avg Forecast
$31.40+156.75%
Max Forecast
$38.00+210.71%

Should I buy or sell CGEM stock?

Based on 5 analysts offering ratings for Cullinan Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CGEM's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CGEM as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their CGEM stock forecasts and price targets.

CGEM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-02
lockedlocked$00.00+00.00%2026-01-08
lockedlocked$00.00+00.00%2025-12-09
lockedlocked$00.00+00.00%2025-11-24Find Out Why
lockedlocked$00.00+00.00%2025-08-18

1 of 1

Forecast return on equity

Is CGEM forecast to generate an efficient return?

Company
-41.65%
Industry
335.63%
Market
216.58%
CGEM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CGEM forecast to generate an efficient return on assets?

Company
-38.83%
Industry
119.72%
CGEM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CGEM earnings per share forecast

What is CGEM's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
-$3.18
Avg 2 year Forecast
-$2.81
Avg 3 year Forecast
-$3.43

CGEM revenue forecast

What is CGEM's revenue in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
$22.8M
Avg 2 year Forecast
$24.1M
Avg 3 year Forecast
$21.2M

CGEM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CGEM$12.23$31.40+156.75%Strong Buy
DBVT$21.26$46.00+116.37%Strong Buy
ABUS$3.84$5.00+30.21%Strong Buy
JBIO$15.32$22.60+47.52%Strong Buy
NKTR$36.81$116.20+215.68%Strong Buy
View Top Biotech Stocks

Cullinan Therapeutics Stock Forecast FAQ

Is Cullinan Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: CGEM) stock is to Strong Buy CGEM stock.

Out of 5 analysts, 3 (60%) are recommending CGEM as a Strong Buy, 2 (40%) are recommending CGEM as a Buy, 0 (0%) are recommending CGEM as a Hold, 0 (0%) are recommending CGEM as a Sell, and 0 (0%) are recommending CGEM as a Strong Sell.

If you're new to stock investing, here's how to buy Cullinan Therapeutics stock.

What is CGEM's earnings growth forecast for 2026-2028?

(NASDAQ: CGEM) Cullinan Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.03%.

Cullinan Therapeutics's earnings in 2026 is -$219,458,620.On average, 14 Wall Street analysts forecast CGEM's earnings for 2026 to be -$187,620,291, with the lowest CGEM earnings forecast at -$229,842,093, and the highest CGEM earnings forecast at -$132,744,354. On average, 10 Wall Street analysts forecast CGEM's earnings for 2027 to be -$165,933,396, with the lowest CGEM earnings forecast at -$211,894,726, and the highest CGEM earnings forecast at -$50,244,358.

In 2028, CGEM is forecast to generate -$202,466,155 in earnings, with the lowest earnings forecast at -$233,894,725 and the highest earnings forecast at -$173,684,201.

What is CGEM's revenue growth forecast for 2026-2028?

(NASDAQ: CGEM) Cullinan Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.06%.

Cullinan Therapeutics's revenue in 2026 is $0.On average, 14 Wall Street analysts forecast CGEM's revenue for 2026 to be $1,347,056,858, with the lowest CGEM revenue forecast at $0, and the highest CGEM revenue forecast at $4,962,405,756. On average, 10 Wall Street analysts forecast CGEM's revenue for 2027 to be $1,424,683,062, with the lowest CGEM revenue forecast at $0, and the highest CGEM revenue forecast at $4,281,315,566.

In 2028, CGEM is forecast to generate $1,251,885,004 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,231,884,901.

What is CGEM's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CGEM) forecast ROA is -38.83%, which is lower than the forecast US Biotechnology industry average of 119.72%.

What is CGEM's Price Target?

According to 5 Wall Street analysts that have issued a 1 year CGEM price target, the average CGEM price target is $31.40, with the highest CGEM stock price forecast at $38.00 and the lowest CGEM stock price forecast at $27.00.

On average, Wall Street analysts predict that Cullinan Therapeutics's share price could reach $31.40 by Feb 2, 2027. The average Cullinan Therapeutics stock price prediction forecasts a potential upside of 156.75% from the current CGEM share price of $12.23.

What is CGEM's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CGEM) Cullinan Therapeutics's current Earnings Per Share (EPS) is -$3.06. On average, analysts forecast that CGEM's EPS will be -$3.18 for 2026, with the lowest EPS forecast at -$3.89, and the highest EPS forecast at -$2.25. On average, analysts forecast that CGEM's EPS will be -$2.81 for 2027, with the lowest EPS forecast at -$3.59, and the highest EPS forecast at -$0.85. In 2028, CGEM's EPS is forecast to hit -$3.43 (min: -$3.96, max: -$2.94).

What is CGEM's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CGEM) forecast ROE is -41.65%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.